These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
245 related items for PubMed ID: 15642078
21. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE. Dornhorst A, Lüddeke HJ, Koenen C, Meriläinen M, King A, Robinson A, Sreenan S, PREDICTIVE Study Group. Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846 [Abstract] [Full Text] [Related]
22. Insulin detemir: a review of its use in the management of diabetes mellitus. Keating GM. Drugs; 2012 Dec 03; 72(17):2255-87. PubMed ID: 23110609 [Abstract] [Full Text] [Related]
23. [Long-term improvement of fasting glycaemia after switching basal insulin from NPH to determir in children with type 1 diabetes: a 1-year multicentre study]. Sumník Z, Venhácová J, Brázdová L, Skvor J. Cas Lek Cesk; 2008 Dec 03; 147(8):421-5. PubMed ID: 18777801 [Abstract] [Full Text] [Related]
26. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes. Bolli GB, Songini M, Trovati M, Del Prato S, Ghirlanda G, Cordera R, Trevisan R, Riccardi G, Noacco C. Nutr Metab Cardiovasc Dis; 2009 Oct 03; 19(8):571-9. PubMed ID: 18676131 [Abstract] [Full Text] [Related]
27. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B, PREFER Study Group. Diabetes Obes Metab; 2009 Jan 03; 11(1):45-52. PubMed ID: 18643839 [Abstract] [Full Text] [Related]
28. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes--the glargine and aspart study (GLASS) a randomised cross-over study. Chatterjee S, Jarvis-Kay J, Rengarajan T, Lawrence IG, McNally PG, Davies MJ. Diabetes Res Clin Pract; 2007 Aug 03; 77(2):215-22. PubMed ID: 17141354 [Abstract] [Full Text] [Related]
29. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Lüddeke HJ. Diabetes Obes Metab; 2007 May 03; 9(3):418-27. PubMed ID: 17391170 [Abstract] [Full Text] [Related]
31. Insulin detemir: a long-acting insulin product. Jones MC, Patel M. Am J Health Syst Pharm; 2006 Dec 15; 63(24):2466-72. PubMed ID: 17158694 [Abstract] [Full Text] [Related]
34. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A, European Insulin Glargine Study Group. Diabetes Metab Res Rev; 2005 Dec 15; 21(6):545-53. PubMed ID: 16021649 [Abstract] [Full Text] [Related]